MPs' pay to soar to £94k in inflation-busting rise
MPs are in line for an inflation-busting 2.8 per cent pay rise this year, the body in charge of parliamentary salaries has announced - in a move that would take their wages to almost £94k.
The Independent Parliamentary Standards Authority (Ipsa), which was set up in the wake of the expenses scandal, said its proposals in part reflect the 'vital role' of MPs.
But critics said it would be a 'bitter pill' to swallow for taxpayers and claimed MPs were being rewarded for failure. And senior citizens accused the government of hypocrisy for entertaining pay rises for MPs while taking winter fuel payments from pensioners.
Campaign group Silver Voices said if the pay rise goes through, 'it will reek of hypocrisy'.
Founder Dennis Reed told The Independent: 'To be in an apparent financial situation so dire a hard decision had to be taken to deprive 10 million old people of winter fuel payments, but now the situation is apparently not hard enough for there to not be above inflation pay rises for MPs.
'One can't really argue MPs have been struggling for every penny, so it reeks of hypocrisy and will not go down well with pensioners.'
Ipsa chairman Richard Lloyd said: "IPSA has been responsible for deciding MPs' pay since 2011. Since then, our aim has been to make fair decisions on pay, both for MPs and the public.
"Our pay proposal for 2025-26 reflects the experience of the wider working public sector population, and recognises both the vital role of MPs and the current economic climate."
If approved, the increase would take an MP's annual salary to £93,904, up from £91,346.
John O'Connell, chief executive of the TaxPayers' Alliance, said: "This will be a bitter pill to swallow given politicians of both front benches have for years hammered the living standards of taxpayers.
"MPs are guilty of delivering a record high tax burden, persistent inflation and struggling services, yet are now being rewarded for this catalogue of failures.
"Pay for politicians should be strictly linked to the country's economic performance, ideally to actual living standards measured by GDP per capita."
Last March, No 10 said then prime minister Rishi Sunak would accept an inflation-busting 5.5 per cent increase in his MP's pay after Ipsa recommended the basic salaries be increased from £86,584.
The rise was higher than the rate of Consumer Prices Index (CPI) inflation.
At that stage Ipsa said the decision had been taken in line with the award recently agreed for the senior civil servants.
At the start of the last Parliament, in 2019, MPs were paid £79,468.
The latest Ipsa proposal is in line with the government's recommendations on a wider public sector pay increase for this year and slightly above the current inflation rate of 2.5 per cent.
Mr Reed added: 'It is a fundamental blunder and will be the legacy of this government, Thatcher the milk snatcher lived on… this is going to live on, too.'
Ministers are also paid a separate salary on top of being an MP.
Ipsa will consult on its proposals until mid-March. It is also carrying out a wider review of MPs' salaries, which it is obliged to do in the first year after an election.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
How reliable is U.S. economic data? It's a growing risk for investors awaiting the next Fed rate cut.
Investors have been navigating an increasingly hazy outlook for the U.S. economy, as surveys of consumer sentiment have appeared to clash with so-called hard data regarding the state of the labor market. Creeping doubts about the quality of U.S. economic reports certainly won't make this task any easier. I have $1,000 in credit-card debt. Will I be able to hide my inheritance from the bank? 'He failed in his fiduciary duty': My brother liquidated our mother's 401(k) for her nursing home. He claimed the rest. I bought my mother-in-law a condo — and she took out a $30,000 car loan. Now she refuses to get a roommate. Third time lucky? Citi changes its S&P target once more after index hits 6,000. 'It might be another Apple or Microsoft': My wife invested $100K in one stock and it exploded 1,500%. Do we sell? Fresh questions about the reliability of official data surfaced this week, after the Bureau of Labor Statistics said that it had to cut back on some regional collection efforts that were part of the tabulation of the consumer-price index in April, and again in June, because 'current resources can no longer support the collection effort.' The cutbacks, caused by a federal government hiring freeze, won't impact the headline CPI numbers that investors tend to focus on most closely, the agency said in a statement published on its website — although it could increase the volatility of certain details within the report. A representative for the BLS didn't offer any further comment when contacted by MarketWatch. See: There's a frenzy in Washington over the accuracy of a key measure of U.S. inflation. Here's what's happening. The next iteration of the CPI report, which would offer investors the first major insight into the level of inflation in May, is due to be released on Wednesday. Another inflation reading focused on producer prices will follow a day later. For decades, U.S. economic data were widely considered the most comprehensive and most reliable among major developed economies. But recently, some economists and investors have highlighted what they see as flaws or shortcomings that could impact key economic reports, including labor data like the monthly nonfarm-payrolls report released this past Friday. 'This is a problem that we all kind of know about, but we just kind of ignore it and move forward because perception is reality in this market,' said Eric Pachman, chief analytics officer at Bancreek Capital Advisors, during an interview with MarketWatch on Friday. The Federal Reserve relies on the personal-consumption expenditures (PCE) price index, a separate inflation gauge, as the basis for its policy decision-making. The central bank outsources the collection of these data to federal statistical agencies. Given the influence that Fed policy decisions have on financial markets, this could become a problem for investors down the road. It is not just the BLS's stymied collection method for CPI that is contributing to these doubts. Questions about official methodologies used to calculate certain reports have been percolating for more than a year now, and they found their way back into the conversation on Wall Street this past week. On Thursday, Steven Englander, head of global G-10 FX research and North American macro strategist at Standard Chartered, published a report highlighting what he described as inconsistencies between the Labor Department's monthly jobs report and a quarterly employment reading that is seen as more reliable, but released with a longer lag. In the report, Englander said that some of the methods used by the BLS when calculating the monthly figures might be causing this. Whether or not these issues could lead to a Fed 'policy mistake' that leads to negative consequences for markets and the economy is hard to say, Englander told MarketWatch. The central bank uses a panoply of data to inform its assessments regarding the strength of the labor market and inflation, the two sides of the central bank's dual mandate. However, if the Fed had access to more accurate data earlier, it might have held off on one of the interest-rate hikes it delivered in 2023 while potentially moving more quickly to cut borrowing costs, Englander said. The central bank ultimately lowered its policy rate in September for the first time since the pandemic. Many recent monthly reports have seen the headline number that investors tend to focus on later revised lower. When the reading for May was released on Friday, it included downward revisions to data from the prior two months. Last year, officials revealed that the U.S. economy had added 818,000 fewer jobs than previously reported between the spring of 2023 and the spring of 2024. Steve Dean, chief investment officer at Compound Planning, warned that the issues with the BLS's collection efforts tied to its inflation reports have cropped up at a particularly inopportune time. Investors and policymakers alike are still struggling to untangle how President Trump's tariffs might impact inflation and the labor market. 'Any reduction in the quality and reliability, and therefore the confidence, in that data makes the Fed's job harder,' Dean, who began his career in economic research at the Fed, told MarketWatch in a statement shared via email. 'This is crucial in the current environment when investors are trying to gauge the balance between inflation and employment and how that will lead the Fed to act,' Dean added in comments shared via email. Michael Brown, a senior research strategist at Pepperstone, told MarketWatch that concerns about the quality of economic data have been gaining traction recently, and not just in the U.S. Problems with the accuracy of economic data have cropped up in the U.K., where Brown is based. 'Frankly, it's a huge issue,' Brown told MarketWatch via email. 'Every market participant and policymaker (both monetary & fiscal) is relying on data being accurate in order to make the most effective decisions that they can. If one has to question the figures that are being received, then it will clearly lead to those decisions being less effective.' U.S. stocks finished higher on Friday, with the S&P 500 SPX closing above 6,000 for the first time since February, according to Dow Jones Market Data. The Nasdaq Composite COMP also logged its highest close since February, while the Dow Jones Industrial Average DJIA saw its highest close since May 19. 'The situation is extreme': I'm 65 and leaving my estate to only one grandchild. Can the others contest my will? My new husband gave me a contract and told me to 'sign here' — but I refused. It was the best decision of my life. 'I'm not wildly wealthy, but I've done well': I'm 79 and have $3 million in assets. Should I set up 529 plans for my grandkids? My local restaurant charges a 5% container fee and 3% kitchen-service charge. Should I refuse to pay? My daughter's boyfriend, a guest in my home, offered to powerwash part of my house — then demanded money
Yahoo
6 hours ago
- Yahoo
US Treasuries Win Some Respite as Key 30-Year Auction Looms
(Bloomberg) -- US Treasuries were trimming overnight gains, with modest weakness in longer dated debt as investors awaited a Thursday auction of 30-year securities that will offer a fresh test of demand for the beleaguered securities. Next Stop: Rancho Cucamonga! Where Public Transit Systems Are Bouncing Back Around the World Trump Said He Fired the National Portrait Gallery Director. She's Still There. US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Senator Calls for Closing Troubled ICE Detention Facility in New Mexico An early rally that mirrored moves in European bonds lost steam ahead of the Wall Street open for equity trading. Treasuries were clinging to gains on maturities out to the 10-year. That left US government bonds still nursing the bulk of sharp losses from Friday's stronger-than-expected US jobs report that saw traders dial back Federal Reserve interest rate cut expectations. A quieter day for economic data Monday is shifting attention to US and China trade talks in London, and events later this week, including consumer inflation on Wednesday and the debt sale the following day. While scheduled bond auctions are typically routine affairs, Thursday's $22 billion offering will be particularly scrutinized given the recent volatility in long-dated global bonds. Yields have soared in recent weeks amid growing concern over major governments' spiraling debt and deficits. 'The 30 year is a kind of tail risk type of rate,' said Jeffrey Klingelhofer, portfolio manager at Aristotle Pacific Capital LLC in Newport Beach. 'Concerns over deficit spending' matter far more for the long end than, 'the seven to 10 year and certainly the shorter part of the curve,' he said. The US 30-year yield has been marching higher since early April, hitting a peak of 5.15% on May 22, the highest since 2023. It was up around two basis points at 4.99%, from a session low of 4.94% on Monday, while the 10-year yield hovered around 4.51%. 'This is going to be key and really set the tone into June as a whole,' said Lauren van Biljon, fixed income portfolio manager at Allspring Global Investments, on Bloomberg TV, about the 30-year Treasury auction. 'We know how much anxiety there is around longer-term financing.' Mike Riddell, a portfolio manager at Fidelity International, said he's entered a steepener position, which profits from long-dated bonds underperforming shorter ones. Like PGIM Fixed Income, he said the forces driving ultra-long bonds have shifted away from monetary policy. 'It's no longer about policy rates, it's all about the fiscal story and demand supply dynamics,' Riddell said. It's 'really concerning' that there 'doesn't appear to be any change in policy on the back of these market moves,' he added. The US will also hold auctions for three and 10-year notes on Tuesday and Wednesday, respectively. Bond traders must also navigate the May CPI report, with economists surveyed by Bloomberg forecasting the year-on-year rate ticking up from 2.3% to 2.5%. 'Signs of inflation pressure could knock risk sentiment, and it may even limit dollar upside, especially if it threatens the US's 30-year Treasury auction on Thursday,' Kathleen Brooks, research director at XTB wrote in a note. --With assistance from Alice Atkins and Michael Mackenzie. (Updates yields, adds quote in fourth paragraph.) The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again America Cast Itself as the World's Moral Leader. Not Anymore Is Elon Musk's Political Capital Spent? What Does Musk-Trump Split Mean for a 'Big, Beautiful Bill'? ©2025 Bloomberg L.P.
Yahoo
7 hours ago
- Yahoo
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) TAMPA, Fla., June 2, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned Phase 3 accelerated approval trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025, in Chicago, Illinois. The Company's poster, titled "Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC)" details the Company's Phase 3 accelerated approval trial design of IFx-Hu2.0, its novel innate immune agonist. The Trial in Progress poster was presented by Andrew Brohl, M.D., Medical Oncologist at Moffitt Cancer Center, and highlighted the importance of innate immune system activation in Merkel cell carcinoma patients with primary resistance to checkpoint inhibitors (CPIs). "Merkel cell carcinoma is a rare and aggressive tumor type. While checkpoint inhibitor therapy has markedly improved the outcome for patients with advanced or metastatic MCC, unfortunately for patients who don't respond to first line checkpoint inhibitor therapy the survival is poor at less than 30 months.1 Based on the results from our Phase 1 clinical trials, IFx-Hu2.0 intralesional administration has demonstrated it can activate an innate immune response, resulting in the production and activation of tumor specific B cells and T cells, to overcome the primary CPI resistance in both advanced or metastatic MCC or melanoma," stated James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences. "We believe we have provided data requested by the FDA that addresses the requirements listed in the partial clinical hold letter to allow us to initiate our Phase 3 accelerated approval trial this month. The FDA was constructive in the trial design, which can potentially satisfy both the requirements for accelerated and regular approval without the requirements for a post approval confirmatory trial. They continue to work with us under the SPA Agreement in preparing the trial's initiation." In the Phase 1b trial of IFx-Hu2.0, MCC among patients who progressed on pembrolizumab (anti-PD-1) or avelumab (anti-PDL-1) therapy, weekly administration of IFx-Hu2.0 for up to 3 doses followed by rechallenge with anti-PD(L)-1 therapy, demonstrated an overall response rate of 63% (2CR, 5 PR) with duration of responses ranging from 6 to 33 months with 5 ongoing responses as of last follow-up in June 2024. The Company's Phase 3 accelerated approval trial of adjunctive IFx-Hu2.0, to be conducted under a SPA agreement with the U.S. FDA, will evaluate IFx-Hu2.0 (0.1 mg) as an adjunctive therapy administered weekly for three weeks concurrent to pembrolizumab (200 mg) Q3W, compared to the same pembrolizumab regimen plus placebo. The pivotal trial is expected to enroll 118 CPI-naïve patients with advanced or metastatic MCC across approximately 22 to 25 U.S. sites. Trial participants will be randomized on a 1:1 basis and receive CPI therapy for up to two years, or until disease progression or CPI related toxicities. The primary endpoint for the trial is overall response rate (ORR) with a key secondary endpoint of progression free survival (PFS). Other secondary endpoints are safety, duration of response, and overall survival. The Trial in Progress poster is available on the Scientific Publications page of TuHURA's website. 1 Kacew et al. (2020). Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget, 11(47), 4401–4410. About TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune agonist product candidates, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. For more information, please visit and connect with TuHURA on Facebook, X, and LinkedIn. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding TuHURA's IFx-Hu2.0 product candidate and anticipated Phase 3 trial and any developments or results in connection therewith and the anticipated regulatory pathway and timing thereof. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities. Investor Contact: Monique KosseGilmartin GroupMonique@ View original content to download multimedia: SOURCE TuHURA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
